The Global Hepatitis C Drugs Market Continues To Grow Owing To the High Incidence of Hepatitis C in the World
![]() |
Hepatitis C Drugs |
Hepatitis C Drugs Market, by Drug Type (Interferon Based Therapies,
NS5A Inhibitors, NS5B Inhibitors, and Protease Inhibitors), by Distribution
Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by
Region (North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027.
Market Overview:
The Hepatitis C virus causes an infection of
the liver, which can be a serious illness. Hepatitis C can lead to liver
failure and even cancer if it is not treated. Fortunately, there are several
treatment options to cure this disease and lower the risk of these
complications. Acute hepatitis C can be treated by taking antiviral medicines.
These medications can clear hepatitis C, usually within 6 months. Chronic
hepatitis C is more serious and can lead to severe liver damage and even death.
Most people who get chronic hepatitis C will need to take medications for the
rest of their lives unless they have liver transplants. Tests to detect
hepatitis C include HCV RNA and liver function tests. These tests measure the
number of viral RNA (genetic material from the hepatitis C virus) particles and
enzyme levels in the liver.
Competitive Landscape:
Major players operating in the global Hepatitis
C Drugs Market include
Kadmon Holdings, Inc., Natco Pharma Limited, Johnson & Johnson, Merck &
co., Inc., F Hoffmann-la Roche Ltd, BRISTOL-MYERS Squibb Company., Gilead
sciences, Inc., and Abbvie Inc.
Key Market Drivers:
The increasing incidence of hepatitis C
infections in the world is expected to augment the growth of the global Hepatitis C Drugs Market. For instance,
according to the World Health Organization, globally around 58 million
individuals suffer from chronic hepatitis C virus infection, and around 1.5
million new cases occur every year. The hepatitis C virus can live in the liver
for years before showing any symptoms, so these tests are important to detect
the infection. The doctor will do blood tests to check for hepatitis C. Having
these tests will also help identify which types of medications patients need to
take for treatment. Moreover, the high prevalence of pharmaceutical and biotech
sectors in the world is estimated to enhance the growth of the global hepatitis
C drugs market.
Covid-19 Impact Analysis:
During the COVID-19 pandemic, the global Hepatitis C Drugs Market witnessed
several challenges. The increasing burden on the healthcare sector restrained
the growth of the market. Moreover, several pharmacological and
biotechnological processes were postponed, which impacted market growth.
Key Takeaways:
· North America is expected to dominate the
growth of the global Hepatitis C Drugs
Market, owing to the high incidence of hepatitis C cases in the region. For
instance, according to the United States National Institute of Diabetes and
Digestive and Kidney Diseases, around 3.9 million individuals in the United
States suffer from chronic hepatitis C infections.
· The Asia Pacific is estimated to witness high
growth in the global hepatitis C drugs market, owing to the increasing approval
of hepatitis C drugs in the region. For instance, according to The Times of
India, Natco Pharma introduced a fixed dose combination of
Sofosbuvir-Daclatasvir tablets, in order to treat hepatitis C infections.
Comments
Post a Comment